149 related articles for article (PubMed ID: 16133794)
1. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Lopez-Lazaro L; Beijnen JH; Schellens JH
Invest New Drugs; 2005 Oct; 23(5):429-36. PubMed ID: 16133794
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Hillebrand MJ; Bosch TM; Lopez-Lazaro L; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2007 May; 59(6):825-37. PubMed ID: 16988825
[TBL] [Abstract][Full Text] [Related]
3. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Sparidans RW; Rosing H; Hillebrand MJ; López-Lázaro L; Jimeno JM; Manzanares I; van Kesteren C; Cvitkovic E; van Oosterom AT; Schellens JH; Beijnen JH
Anticancer Drugs; 2001 Sep; 12(8):653-66. PubMed ID: 11604552
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Zelek L; Yovine A; Brain E; Turpin F; Taamma A; Riofrio M; Spielmann M; Jimeno J; Misset JL
Br J Cancer; 2006 Jun; 94(11):1610-4. PubMed ID: 16736024
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C; Twelves C; Bowman A; Hoekman K; López-Lázaro L; Jimeno J; Guzman C; Mathôt RA; Simpson A; Vermorken JB; Smyth J; Schellens JH; Hillebrand MJ; Rosing H; Beijnen JH
Anticancer Drugs; 2002 Apr; 13(4):381-93. PubMed ID: 11984084
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
[TBL] [Abstract][Full Text] [Related]
10. Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.
Stokvis E; Rosing H; López-Lázaro L; Beijnen JH
J Mass Spectrom; 2004 Apr; 39(4):431-6. PubMed ID: 15103657
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Villalona-Calero MA; Eckhardt SG; Weiss G; Hidalgo M; Beijnen JH; van Kesteren C; Rosing H; Campbell E; Kraynak M; Lopez-Lazaro L; Guzman C; Von Hoff DD; Jimeno J; Rowinsky EK
Clin Cancer Res; 2002 Jan; 8(1):75-85. PubMed ID: 11801542
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
14. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
Ryan DP; Puchalski T; Supko JG; Harmon D; Maki R; Garcia-Carbonero R; Kuhlman C; Winkelman J; Merriam P; Quigley T; Jimeno J; Manola J; Demetri GD
Oncologist; 2002; 7(6):531-8. PubMed ID: 12490740
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Lau L; Supko JG; Blaney S; Hershon L; Seibel N; Krailo M; Qu W; Malkin D; Jimeno J; Bernstein M; Baruchel S
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):672-7. PubMed ID: 15701855
[TBL] [Abstract][Full Text] [Related]
16. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
van Kesteren C; Mathĵt RA; López-Lázaro L; Cvitkovic E; Taamma A; Jimeno JM; Guzman C; Schellens JH; Misset JL; Brain E; Hillebrand MJ; Rosing H; Beijnen JH
Cancer Chemother Pharmacol; 2001 Dec; 48(6):459-66. PubMed ID: 11800026
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
Ueda T; Kakunaga S; Ando M; Yonemori K; Sugiura H; Yamada K; Kawai A
Invest New Drugs; 2014 Aug; 32(4):691-9. PubMed ID: 24696229
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.
Thariat J; Etienne-Grimaldi MC; Launay-Vacher V; Soto-Matos A; Fernandez-Teruel C; Ghafari T; Marcy PY; Milano G; Renée N; Gastaud L; Thyss A
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1363-7. PubMed ID: 21850465
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.
Vermeir M; Hemeryck A; Cuyckens F; Francesch A; Bockx M; Van Houdt J; Steemans K; Mannens G; Avilés P; De Coster R
Biochem Pharmacol; 2009 May; 77(10):1642-54. PubMed ID: 19426702
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Chuk MK; Aikin A; Whitcomb T; Widemann BC; Zannikos P; Bayever E; Balis FM; Fox E
Pediatr Blood Cancer; 2012 Nov; 59(5):865-9. PubMed ID: 22847981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
